Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celecoxib plus fluoxetine for depression in patients with irritable bowel syndrome
IRCT20200517047476N1Phase 3Completed
- Sponsor
- Kurdistan University of Medical Sciences
- Start
- Jul 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of celecoxib and fluoxetine in major depressive disorder (MDD) and irritable bowel syndrome (IBS) (2 arms), sponsored by Kurdistan University of Medical Sciences. Primary endpoint: Depression score in Beck Depression Questionnaire at Day 42. Started Jul 2020; status: completed.
02
Drugs
celecoxibfluoxetine
03
Conditions
major depressive disorder (MDD)irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on IRCT20200517047476N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200517047476N1.